These findings reveal a complex dual-pathway regulation of cardiac function by FABP4 and identify its N-terminal region as a potential therapeutic target for mitigating obesity-related cardiac dysfunction. This evidence concerns the gene FABP4 and obesity due to melanocortin 4 receptor deficiency.